Advertisement
ALNY or PRAX or VRTX
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Praxis Precision Medicines (PRAX) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- ALNY delivered strong YTD gains of 20.61% with consistent revenue growth from RNAi therapeutics, bolstered by recent partnerships and a new five-year strategy.
- PRAX exploded 696.76% over the past year on CNS pipeline momentum, including NDAs and Phase 3 progress, though high beta signals elevated volatility.
- VRTX offers stability with a low beta of 0.31, positive Phase 3 kidney data driving recent surges, and robust profitability among the trio.
- ALNY and VRTX show profitability with reasonable forward valuations, contrasting PRAX's pre-revenue high-growth profile.
- Biotech sector exposure highlights contrasts in rare disease focus versus CNS innovation, with relative performance favoring momentum in PRAX amid market positioning.
- All three exhibit low-to-moderate recent drawdowns, appealing for traders eyeing catalysts in clinical advancements and partnerships.
Introduction
This comparison examines ALNY, PRAX, and VRTX, three biotech leaders in rare disease and precision medicine arenas. Investors tracking relative performance in innovative therapeutics—such as RNAi silencing, CNS modulation, and CF treatments—will find value here. Amid recent clinical milestones and market volatility, these stocks highlight trade-offs in growth potential, stability, and valuation sensitivity. Traders seeking momentum plays or defensive biotech exposure can assess how recent developments shape their market positioning in the evolving healthcare landscape.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals, Inc. (market cap ~$42B) pioneers RNA interference (RNAi) therapeutics for rare genetic diseases, with approved products like AMVUTTRA for ATTR amyloidosis and a pipeline targeting hypertension, metabolic disorders, and neurodegeneration. Trading around $316 with a 52-week range of $206–$496, ALNY posted YTD returns of 20.61% and 30.58% over one year, reflecting solid momentum. Recent weeks saw share pressure despite strong Q4 2025 results—nearly $3B in product revenues, up 81% YoY—and profitability. Sentiment shifted positively on the "Alnylam 2030" strategy launch, a $250M manufacturing expansion, and partnerships like Tenaya Therapeutics for cardiovascular RNAi targets. Low beta (0.38) underscores defensive traits amid clinical progress.
PRAX Overview and Recent Performance
Praxis Precision Medicines, Inc. (market cap ~$8.5B) develops therapies for CNS disorders via neuronal excitation-inhibition imbalance, leveraging Cerebrum small-molecule and Solidus ASO platforms. Key candidates include ulixacaltamide (NDA for essential tremor) and relutrigine (NDA for DEEs). At ~$305, with a 52-week range of $27–$356, PRAX surged 696.76% over one year and 3.48% YTD, driven by explosive growth. Recent market activity featured volatility post-Q4 updates, NDA filings, Breakthrough Therapy designations, and $621M raised via offering, extending runway to 2028. High beta (3.01) reflects sensitivity to pipeline catalysts like 2026 readouts, fueling trader interest despite pre-revenue status and net losses.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals Incorporated (market cap ~$118B) focuses on cystic fibrosis dominance via TRIKAFTA and expansions into SCD, pain (JOURNAVX), and kidney disease. Priced near $466 in a $363–$517 range, VRTX returned 2.81% YTD and 7.66% over one year, prioritizing stability. Recent performance highlighted an 8.3% surge on positive Phase 3 RAINIER interim data for povetacicept in IgA nephropathy, achieving primary and secondary endpoints. Steady revenue (~$12B TTM) and profitability underpin sentiment, tempered by ROIC concerns. Ultra-low beta (0.31) positions it as a biotech anchor amid diversification catalysts.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top performers from hundreds of AI trading bots scanning thousands of tickers for real-time signals across stocks, ETFs, and crypto. Only the most suitable for prevailing volatility—booms in semiconductors, aerospace, energy, and biotech—earn spots, with 25 highlighted from 351 total agents. Stats shine: annualized returns up to +208%, win rates 52–95% (many 80–90%), profit factors 1.6–25+, and trades from days to months. Examples include +130% on multi-sector plays (SOXL, ITA) with 74% wins, and biotech bots at 95% win rates. Diverse styles suit swing, pattern, and hedging in choppy markets. Explore these adaptive strategies at Trending AI Robots to align with current conditions.
Head-to-Head Comparison
ALNY, PRAX, and VRTX converge on biotech innovation but diverge sharply. Business models pit ALNY’s RNAi platform against PRAX’s CNS precision meds and VRTX’s CF/gene therapy stronghold. Growth drivers favor PRAX’s 697% 1Y surge on NDAs versus ALNY’s 81% revenue jump and VRTX’s steady 9–11%. Recent momentum peaks for VRTX (Phase 3 wins) and ALNY (partnerships), while PRAX rides pipeline hype. Risks amplify in high-beta PRAX (losses, volatility) over stable VRTX (beta 0.31). All share rare disease exposure; valuations contrast VRTX’s attractive 30x PE (~$12B revenue) with ALNY’s 135x (profitable) and pre-profit PRAX. Sentiment tilts toward catalysts balancing growth-risk trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently leans toward VRTX for its trend consistency, low volatility (beta 0.31), proven profitability, and fresh Phase 3 catalysts positioning it favorably relative to peers. While PRAX tempts with explosive momentum and ALNY impresses via revenue scaling, VRTX’s stability and sector leadership offer higher-probability outperformance in varied conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s), and VRTX’s FA Score reflects 1 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- PRAX’s FA Score: 0 green, 5 red.
- VRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s), and VRTX’s TA Score reflects 3 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 5 bearish.
- PRAX’s TA Score: 4 bullish, 5 bearish.
- VRTX’s TA Score: 3 bullish, 6 bearish.
Price Growth
ALNY (@Biotechnology) experienced а +0.76% price change this week, while PRAX (@Biotechnology) price change was +3.16% , and VRTX (@Biotechnology) price fluctuated +1.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.26%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +6.73%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
PRAX is expected to report earnings on May 13, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Biotechnology (+2.26% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | PRAX | VRTX | |
| Capitalization | 42.9B | 8.92B | 114B |
| EBITDA | 631M | -326.06M | 4.87B |
| Gain YTD | -19.205 | 8.638 | -1.451 |
| P/E Ratio | 137.89 | N/A | 29.16 |
| Revenue | 3.71B | 0 | 12B |
| Total Cash | 2.91B | 599M | 6.61B |
| Total Debt | 1.28B | 110K | 2.03B |
ALNY | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 49 | 33 | |
SMR RATING 1..100 | 15 | 39 | |
PRICE GROWTH RATING 1..100 | 60 | 59 | |
P/E GROWTH RATING 1..100 | 100 | 49 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VRTX's Valuation (81) in the Biotechnology industry is in the same range as ALNY (94). This means that VRTX’s stock grew similarly to ALNY’s over the last 12 months.
VRTX's Profit vs Risk Rating (33) in the Biotechnology industry is in the same range as ALNY (49). This means that VRTX’s stock grew similarly to ALNY’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as VRTX (39). This means that ALNY’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's Price Growth Rating (59) in the Biotechnology industry is in the same range as ALNY (60). This means that VRTX’s stock grew similarly to ALNY’s over the last 12 months.
VRTX's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for ALNY (100). This means that VRTX’s stock grew somewhat faster than ALNY’s over the last 12 months.
| ALNY | PRAX | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 89% | 1 day ago 70% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 90% | 1 day ago 47% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 90% | 1 day ago 50% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 86% | 1 day ago 42% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 88% | 1 day ago 37% |
| Advances ODDS (%) | 16 days ago 76% | 16 days ago 85% | 1 day ago 62% |
| Declines ODDS (%) | 8 days ago 66% | 3 days ago 84% | 3 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 90% | 3 days ago 74% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 87% | 1 day ago 28% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BBAX | 62.69 | 0.34 | +0.55% |
| JPMorgan BetaBuilders Dev APAC ex-JpnETF | |||
| FXP | 19.95 | 0.10 | +0.52% |
| ProShares UltraShort FTSE China 50 | |||
| PFIG | 24.15 | 0.06 | +0.23% |
| Invesco Fdmtl Invmt Grd Corp Bd ETF | |||
| OAKM | 28.01 | -0.02 | -0.07% |
| Oakmark U.S. Large Cap ETF | |||
| SDS | 68.86 | -0.79 | -1.13% |
| ProShares UltraShort S&P500 | |||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | -0.01% | ||
| BEAM - PRAX | 40% Loosely correlated | +3.50% | ||
| BHVN - PRAX | 37% Loosely correlated | +0.11% | ||
| RAPP - PRAX | 35% Loosely correlated | +1.63% | ||
| VERU - PRAX | 35% Loosely correlated | -4.71% | ||
| RXRX - PRAX | 35% Loosely correlated | -2.06% | ||
More | ||||
VRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with EDIT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +0.64% | ||
| EDIT - VRTX | 38% Loosely correlated | +4.71% | ||
| CRSP - VRTX | 37% Loosely correlated | -0.08% | ||
| MGTX - VRTX | 35% Loosely correlated | -0.53% | ||
| INCY - VRTX | 34% Loosely correlated | +1.12% | ||
| MRNA - VRTX | 34% Loosely correlated | -1.57% | ||
More | ||||